Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – What’s Next?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $109.10 and last traded at $108.64, with a volume of 2089980 shares. The stock had previously closed at $108.17.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Stock Performance

The stock has a market cap of $12.33 billion, a P/E ratio of 32.43, a PEG ratio of 0.43 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a 50-day simple moving average of $83.19 and a 200-day simple moving average of $73.74.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock valued at $5,226,496 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. MidFirst Bank bought a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $28,000. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the second quarter valued at approximately $30,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.